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PREFACE
This report uses data gathered by surveillance systems operated by the Health Protection Agency’s Centre for
Infections (CfI), Health Protection Scotland (HPS), National Public Health Service for Wales (NPHS), CDSC
Northern Ireland, and other collaborating institutions. Data from research studies undertaken by these
organisations in collaboration with the Centre for Research on Drugs and Health Behaviour (CRDHB) at London
School of Hygiene and Tropical Medicine, the School of Social Sciences at the University of Paisley, and the
Centre for Drugs Misuse Research at the University of Glasgow have also been included.
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Key Messages
1. Almost three-quarters of injecting drug users have ever
been homeless, and those who have been homeless
have higher levels of injecting risk and associated
infections.
2. Injecting into the groin and the injection of crack-
cocaine, which are both associated with higher levels
of infection and injecting risk, have become more
common. 
3. Overall hepatitis C infection among injecting drug
users has increased in recent years, with almost half
now infected.
4. The level of HIV infection in England and Wales among
injecting drug users has increased since the start of
the decade to one in 75.
5. There has been a marked increase in the number of
injecting drug users receiving the hepatitis B vaccine,
with two-thirds now reporting vaccination.
6. Services to reduce injecting related harms and support
those who want to stop injecting should continue to
be developed in line with published guidance.
Key Findings
Behaviours: Levels of reported needle and syringe
sharing increased in the late 1990s, and since then have
remained elevated. A quarter of injecting drug users
(IDUs), reported sharing in the previous month in 2006.
The sharing of other injecting equipment remains even
more common. There are also indications that injecting
into the groin (femoral vein) is becoming more common
with almost one in three IDUs reporting this in 2006. The
use of crack-cocaine has become more widespread with
one in three injecting this drug in 2006; this is a cause for
concern as those injecting crack-cocaine report more
equipment sharing.
Hepatitis C: Overall, almost half of IDUs in the UK have
been infected with hepatitis C. However, there are marked
variations in hepatitis C prevalence within the United
Kingdom (UK), with low prevalences found in some areas.
There are indications that the overall prevalence of
hepatitis C infection among IDUs has probably increased in
recent years and that current levels of hepatitis C
transmission remain elevated.
HIV: The prevalence of HIV infection among IDUs, in
England & Wales, is higher than at the start of the decade.
Overall, around one in 75 IDUs now have HIV infection,
which is still low compared to many other countries. The
prevalence remains elevated among current IDUs in
London with around one in 20 HIV-infected. Within
England and Wales the HIV prevalence has increased most
outside London: where the prevalence has risen from
around one in 400 in 2002 to about one in 150 in 2006.
In Scotland, however, prevalence has remained within one
in 100 and one in 200 range since 1998.
Voluntary confidential diagnostic testing: Uptake of
testing for hepatitis C among IDUs in contact with drug
services has increased noticeably in recent years. It is
estimated, however, that almost half of IDUs with hepatitis
C in contact with these services are unaware of their
infection. There are also likely to be many current and
former IDUs not in contact with services that will be
unaware they have hepatitis C. Whilst most IDUs in contact
with services report having had a test for HIV at some
point, only two-thirds of those with HIV are aware of their
infection. 
Vaccination: The proportion of IDUs reporting uptake of
hepatitis B vaccination has increased markedly in recent
years, with around two-thirds now reporting accepting at
least one vaccine dose. However, the transmission of
hepatitis B continues among IDUs. 
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Summary & Recommendations
Bacterial infections: Around one-third of IDUs report
having had an abscess, sore or opened wound at an
injecting site in the last year, indicating that injecting site
infections are common. There are also continuing
problems ranging from localised injection site infection
through to invasive disease associated with meticillin
resistant Staphylococcus aureus and severe group A
streptococcal infection. The ongoing occurrence of wound
botulism cases remains a concern. 
Homelessness: Data presented in this report indicate
that:
• Around three-quarters of IDUs have ever been
homeless, and around half of those who had been
homeless reported a period of homelessness during
the last 12 months.
• One in four of those who had been homeless reported
the direct sharing of needles and syringes in the past
month compared with only one in six of those who
had not been homeless.
• Those who had been homeless during the last year
were more likely to report an abscess, open sore or
wound at an injecting site. 
• A higher proportion of those who had been homeless
had hepatitis C infection.
• Homelessness has been associated with higher levels
of hepatitis C transmission among IDUs in south Wales.
• A study in Glasgow highlighted that hostels for the
homeless could be foci for high-risk injecting
behaviour.
During periods of homelessness injectors are likely to find
it harder to maintain hygienic injection practices as a result
of having to inject in public places or having difficulty in
storing injecting equipment somewhere clean. Hostels and
other services for the homeless have an important role to
play in reducing such harm. 
Priorities for the Commissioning of Services for
Drug Users
When commissioning community based services to reduce
the harm associated with problem drug use, in line with
the aims of the national drug strategies2,3,4,5,6, primary care
bodies* and Drug Action Teams or local partnerships
should give priority to preventing the spread of infections
among IDUs and reducing the harm that these infections
cause. This should be through:
1. Continuing the development of high-quality needle-
exchange (NEX) services for those unable to stop
injecting (including those using drug treatment
services), by:
a) ensuring sufficient distribution of injecting
equipment to prevent the sharing of needles and
syringes; 
b) providing injecting-related equipment other than
needles and syringes as appropriate to support
hygienic injecting practice; 
c) ensuring an appropriate range of NEX services are
provided, including provision by drug services, retail
pharmacies, and mobile or outreach services; and 
d) providing services that are easily accessible
throughout the week (including evenings,
weekends, and public holidays). 
2. Ensuring that all those services working with IDUs
(including drug treatment services, GPs and NEX),
provide: 
a) information and practical advice on safer injecting
practices, avoiding injecting site infections,
prevention of blood-borne virus transmission, and
the safe disposal of used equipment; 
b) onsite hepatitis B vaccination services, with follow-
up strategies for those who have started the
vaccination course in line with national service
specifications7; 
c) easy access to health checks, treatment for
injection site infections, and diagnostic tests for
hepatitis C and HIV; 
d) interventions to encourage behaviour change away
from the sharing of injecting equipment and to
decrease or stop injecting; and
e) interventions that support entry into drug
treatment, particularly to sustained quality
substitute opioid treatment for heroin users which
has been shown to be protective against infections. 
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* Primary Care Trust in England, Local Health Care Co-operatives and NHS Boards in Scotland, Local Health Boards in
Wales, and Health and Social Services Boards supported by Local Health and Social Care Groups in Northern Ireland.
3. Developing mechanisms, with local providers, to
ensure that services that aim to prevent or reduce
infections among IDUs, such as NEX, can work
effectively with homeless IDUs, and can respond in a
timely fashion to evolving patterns of drug use (such
as increased crack-cocaine use) and risks associated
with injecting practices (such as groin injecting). 
4. Further improving access to diagnostic testing for
hepatitis C and referral pathways for those infected for
specialist assessment and treatment in line with
strategies such as the Hepatitis C Action Plan for
England 8, the Hepatitis C Action Plan for Scotland 9 and
The Action Plan for the Prevention, Management and
Control of Hepatitis C in Northern Ireland 10. 
5. Developing drug treatment services in line with the
recently updated guidelines: “Drug Misuse and
Dependence: Guidelines for Clinical Management” 11,
and the recent National Institute for Health and Clinical
Excellence (NICE) guidance12,13.
6. Developing procedures for offering the tetanus
vaccine and boosters to those IDUs who may need
them and offering hepatitis A vaccination where
appropriate14. 
7. Supporting partnership working between services for
drug users and those agencies working with the
homeless to ensure appropriate delivery of services,
such as, NEX, vaccinations, and drug treatment to
homeless drug users.
8. Promoting a range of easily accessible drug treatment
and support services that encourage drug users to
reduce and cease injecting, and reduce or stop their
drug use. 
The planning of the provision of these, and other services
for drug users, should be based on local needs
assessments, which have been informed by local estimates
of numbers of drug users and injectors, estimates of the
prevalence of infection amongst these populations, and
the particular needs of discrete groups such as homeless
IDUs15. Findings from the National Treatment Agency for
Substance Misuses and Health Care Commission joint
review on Harm Reduction, due in the autumn of 2007,
will provide information on local performance in England. 
In England, the recently revised Models of Care16, which
provides a framework for the provision of treatment to
drug users, sets a clear structure for the provision of
services across the range of providers working with drug
users, and the recent introduction of the Treatment
Outcome Profile17 in England will encourage regular review
and monitoring of injecting behaviour through care plan
reviews. The implementation of the recently launched
Action Plan for Reducing Drug Related Harm in England,
which includes infections as one of its foci18, is providing
additional resources to support service development. 
Priorities for public health surveillance
development and research 
In commissioning developments to public health
surveillance and research studies the following need to be
prioritised:
1. The Unlinked Anonymous Prevalence Monitoring
Programme (UAPMP) survey of IDUs continues to
provide important data and needs to be maintained as
services for drug users develop. As part of Phase 1 of
Scotland's Hepatitis C Action Plan9, the Scottish
Executive has funded a comparable national survey of
hepatitis C and behaviours among IDUs. This initiative
will provide key data to better target and evaluate
interventions aimed at reducing the spread of
infection among this population group. The pilot of
the enhancement to the UAPMP survey of IDUs has
provided useful additional data and the continuation
of such an enhancement survey should be considered. 
2. It is of concern that laboratory data on acute hepatitis
B is currently unavailable, and the quality of the data
on hepatitis A is consistently poor. Improving the
quality and consistency of the surveillance of viral
hepatitis, through the more complete reporting of
laboratory diagnoses with clinical and risk factor
information, is needed. This should build upon the
work now being undertaken, as part of the
implementation of national standards for the
surveillance of hepatitis B and C in the HPA19, to collate
at a national level data on acute hepatitis B cases from
local health protection units. Provisional data will be
available from the start of 2007, however the quality
and completeness of this information is uncertain, and
the interpretation of trends in incidence will be
difficult, given the lack of baseline data.
3. There is a need for research to examine the extent of,
and risk factors associated with, bacterial infections
among IDUs. In addition, there is a need to estimate
the cost to UK health services of bacterial infections
associated with drug injecting, and the feasibility and
cost-savings associated with harm reducing
interventions. Current epidemiological data on
bacterial infections is focused only on the more severe
cases, and there is a need for additional data on
bacterial infections among IDUs. 
4. NEX services are key to preventing infections among
IDUs. Whilst the recent NEX Audits20, 21, have provided
an informative insight, ongoing information on the
extent of provision is needed. The National Treatment
Agency for Substance Misuses is initiating a national
monitoring system of throughput of injecting
equipment in England, which will begin development
in October 2007. This important initiative needs to be
co-ordinated with existing public health surveillance of
IDUs to ensure maximum impact. 
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5. The recent increase in infections among IDUs indicates
a need to re-examine the scope and range of harm
reduction services provided for IDUs. Research projects
to develop, pilot and evaluate novel and improved
service models, which aim to encourage and support
hygienic injection practice, are needed. Research
should also be undertaken to further examine the
impact of unstable housing or homelessness on health
risk among IDUs, the possible shift towards the use of
higher risk injecting sites such as the groin (femoral
vein), and the relationship between crack-cocaine use
and risk. 
1. Injecting drug users (IDUs) are vulnerable to a wide
range of infections, including those caused by viruses
such as HIV and hepatitis C and bacteria such as
Clostridium botulinum and group A streptococci. 
These infections can result in high levels of illness and
death, therefore public health surveillance of infectious
diseases and associated risk and protective behaviours
among this group are important. 
2. The extent of injecting drug use in the United
Kingdom (UK) remains uncertain. A recent national
estimate for England suggested around 140,000
injectors of heroin or crack-cocaine (0.42% of those
aged 15 to 64)22. This number is similar to a pilot back-
calculation model in 2000 which suggested that there
may have been between 100,000 and 150,000 current
opiate using IDUs (0.5% to 0.7% of those aged 15 to
44)23. However, other studies have suggested that the
number of IDUs in England may be higher24. Two
studies funded by the Scottish Executive have provided
estimates of the prevalence of problem drug misuse in
Scotland: these indicated that the number of current
injectors in Scotland may have reduced from around
25,000 in 200025,26, to 19,000 in 200327 (representing
0.9% and 0.7% of those aged 15 to 54 years,
respectively). There are no recent published studies for
Wales or Northern Ireland. Indicators of IDU prevalence
suggest an increase over the long term28. For example,
the National Survey of Sexual Attitudes and Lifestyle
found that the proportion of people reporting ever
injecting increased from 0.8% in 1990 to 1.3% in
200029,30; and the number of opiate overdose deaths
increased five-fold between1990 and 200031. 
3. In 1998 the national drug strategy was launched –
Tackling Drugs to Build a Better Britain32 – and this was
updated in 20022. Scotland6, Wales4 and Northern
Ireland5 have adopted country-specific strategies
within the national one. The government has recently
undertaken a consultation to inform the development
of a revised national strategy, and the Scottish
Executive is currently looking at the best way of
tackling drug use with a view to a new long-term
drugs strategy. There have also been a number of
initiatives, such as the establishment of the National
Treatment Agency for Substance Misuse (NTA) and
Models of Care16,33, in England, to support the
development of services to meet the strategies aims. 
4. This report presents available data on the extent and
trends over time of infections among IDUs in the UK
up to the end of 2006. It includes data on the more
severe bacterial infections affecting IDUs, on available
markers of HIV and viral hepatitis prevalence and
incidence, and on associated risk and protective
behaviours.
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Introduction
5. Infections among IDUs have been associated with a
wide range of behavioural and environmental factors,
such as the sharing of injecting equipment and
homelessness. A range of preventative interventions
have been adopted, such as needle exchange (NEX),
which are designed to reduce the harm associated
with drug use.
England, Wales & Northern Ireland
6. The sharing of needles and syringes (direct sharing) is
a key route by which infections may be transmitted
amongst IDUs. Those IDUs participating in the
Unlinked Anonymous Prevalence Monitoring
Programme’s (UAPMP) survey who reported injecting in
the four weeks prior to taking part in the survey
(current injectors) were asked about direct sharing. In
2006 almost a quarter (23%, 445 of 1,910) reported
sharing in the four weeks before taking part in the
survey. Whilst this is lower than the 34% (601 of
1,775) seen in 2002, it is still higher than the level
seen in the mid 1990’s (Table 1). In England, direct
sharing was reported by 23% (413 of 1,766) in 2006
and, when combining data for 2005 and 2006, 21%
(19 of 90) reported this Northern Ireland and 22% (42
of 195) in Wales.
7. The sharing of filters, mixing containers and flushing
water can also pass on infections, and participants in the
UAPMP survey continued to report sharing of these
items. In England, 45% (797 of 1,784) of current
injectors reported sharing these items in 2006
compared to 48% in 2005. High levels of sharing were
also reported in Wales (49%, 97 of 197) and in Northern
Ireland (30%, 27 of 91) (2005 and 2006 data
combined). The most commonly shared items in
England, Wales and Northern Ireland were mixing
containers such as spoons (38%, 778 of 2,070). 
8. In 2006, almost all the (current and former) IDUs
participating in the UAPMP survey in England reported
that they had ever accessed a NEX service (90%, 2,578
of 2,851). High levels were also found in Wales (92%,
339 of 369) and in Northern Ireland (91%, 275 of 303)
(2005 and 2006 data combined). Throughout England,
Wales and Northern Ireland 91% (2,894 of 3,194)
reported ever accessing a NEX, and amongst recent
initiates (those who reported first injecting during the
previous three years) it was 85% (322 of 379) (Table 1). 
9. The proportion of IDUs who have taken up an offer of
the hepatitis B vaccination has increased markedly over
time, rising from around quarter (25%, 784 of 3,114) in
1998 to two thirds (65%, 2,061 of 3,180) in 2006
(UAPMP survey self-reported data*, Table 1). Self-
reported vaccination uptake varied by region and
country (combining 2005 and 2006 data, Figure 1), and
in Wales was 47% (172 of 367) and in Northern Ireland
76% (230 of 304). Of those who reported vaccination,
almost two thirds self-reported receiving three or more
doses (61%, 1,219 of 1,989), this compares with 42%
(309 of 741) in 1998. In 2006, amongst recent initiates,
61% (235 of 383) reported uptake of the vaccine, which
was higher than in 2005 (46%, 179 of 388).
8 Shooting Up 
An update: October 2007
Risk and Protective Behaviours
Figure 1:
Geographic variations in the prevalence of antibodies to hepatitis C and the uptake* of hepatitis B vaccine among
current & former injecting drug users in England, Wales & Northern Ireland (2005 and 2006 data combined)
* Self reports, those receiving one or more vaccine doses.
Data source: Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact with drug agencies.
Further regional data from this survey is available at: www.hpa.org.uk/infections/topics_az/hiv_and_sti/hiv/epidemiology/ua.htm
* Vaccination uptake data should be interpreted with caution as they are based on self-reports.
Uptake of
hepatitis B vaccination*
70% to 79%
60% to 69%
less than 60%
Proportion with
antibodies to hepatitis C
50% and greater
40% to 49%
30% to 39%
less than 30%
10. The drugs most commonly injected during the past four
weeks by the current IDUs participating in the UAPMP
survey in 2006 (n=1,981) were heroin (87%, 1,730),
crack-cocaine (33%, 657), and amphetamines (15%,
303). The current IDUs who reported injecting crack-
cocaine were more likely to report direct sharing in the
last four weeks (26%, 170 of 645) than those who had
not (22%, 275 of 1,265). 
11. IDUs can inject into a range sites on their bodies, some
of these sites, such as groins (femoral vein), pose a
greater potential risk to health than others. Arms (57%,
1,137) were the most widely used injection site in the
past four weeks among the current IDUs participating in
the UAPMP survey in 2006 (n=1,981). However, a
number of potentially more risky sites were also often
used including: the groin (31%, 623), hands (23%, 461)
and legs (17%, 338). 
12. In 2006, most of the IDUs participating in the UAPMP
survey reported ever having been homeless† (74%,
2,200 of 2,979), with 49% (1,060 of 2,153) of these
having been homeless in the last year. Among recent
initiates 68% (242 of 358) had ever been homeless, and
59% (140 of 236) had been homeless in the last year.
Three quarters of current IDUs had ever been homeless
(77%, 1,420 of 1,840), and those current IDUs who had
been homeless were more likely to report direct sharing
in the last month (25%, 344 of 1,374) than those who
had not (16%, 65 of 400). 
13. The National Public Health Service for Wales (NPHS)
recruited IDUs from both community and treatment
settings in South Wales in to a cohort study in 2004.
They found that among those recruited at the start of
the study 47% (325 of 692) reported having been
homeless during the last year. At follow up, after
approximately one year, 35% (100 of 286) reported
having been homeless during the last year. Amongst
those individuals’ followed-up reported needle and
syringe sharing was higher amongst those who had
been homeless in the previous year; 29% of homeless
individuals reported sharing in the previous year
compared to 14% of housed individuals34.
Scotland
14. In the financial year 2006/07‡, drug treatment agency
reports to the Scottish Drug Misuse Database (SDMD)
indicated that 29%§ of current IDUs had "used a needle
or syringe that someone else had used" in the previous
month. In the financial year 2005/06‡, drug treatment
agency reports to the SDMD found that 27% of current
IDUs had "lent/borrowed/shared" a needle or syringe in
the previous month, which compares with rates in the
range of 31% to 35% during previous years 1998/99 to
2004/05 (Table 1). Given the questions on
needle/syringe sharing were asked differently pre and
post April 2006, the data are not directly comparable
between these two periods.
15. In the financial year 2006/07‡, drug treatment agency
reports to the Scottish Drug Misuse Database (SDMD)
indicated that 39%§ of current IDUs had "used the same
spoon, filter or water as someone else" in the previous
month. In the financial year 2005/06‡, drug treatment
agency reports to the SDMD found that 42% of current
IDUs had "lent/borrowed/shared" a spoon, filter or water
in the previous month, which compares with rates in the
range of 47% to 50% during previous years 2001/02 to
2004/05 (Table 1). 
16. Community-wide surveys of IDUs in Glasgow found a
significant increase in hepatitis B vaccine uptake among
those who had injected for five years or less in 2001/02
(52% of 387) compared to 1993, 1994 and January-
March 1999 (16% of 432)35. Further increases in vaccine
uptake were detected among IDUs, who had injected
for five years or less, surveyed in Glasgow during 2004
(65% of 167) and 2005 (60% of 104). 
17. A recently published study highlighted that Glasgow’s
hostels for the homeless were foci for high-risk injecting
behaviour36. Individuals interviewed during the
qualitative component of the study reported witnessing
prolific sharing of needles and syringes in hostels. While
quantitative data demonstrated a significant association
between living mostly in a hostel in the six months prior
to interview and high-risk injecting behaviour, such as
injecting with and passing on a previously used needle
and syringe. Since this study was conducted in 2001/02,
there have been a number of developments to address
the needs of homeless people in Scotland, including the
establishment of the Glasgow Hostels Decommissioning
Programme37, and the development of Standards on
Health and Homelessness80.
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†  Homeless means living in a hostel, having no fixed abode, or living on the streets.
‡  The SDMD was revised in April 2006, such that data are now collected from clients upon commencement of a new episode of
care rather than each time they attend a new agency. In 2008 data will be collected at defined points throughout a care
episode: i.e. assessment, 3 months, 12 months and annually thereafter. In addition, the questions on sharing of injecting
equipment were revised, as follows: SDMD (pre April 2006) asked "Have you lent/borrowed/shared needles/syringes?" and "Have
you lent/borrowed/shared spoons/water/filters/solutions?"; SDMD (April 2006 - present) asked: "Have you used a needle or syringe
that someone else has used?", "Have you lent someone else a needle or syringe which you have used?" and "Have you used the
same spoon, filter or water as someone else?".
§ Provisional data.
18. IDUs are vulnerable to a range of viral infections
through the use and sharing of contaminated injecting
equipment. Some of these infections, such as hepatitis
C and HIV, cause long-term chronic illnesses that have
asymptomatic phases that can last many years. 
Hepatitis C
19. Hepatitis C is currently the most important infectious
disease affecting those who inject drugs. Very high
prevalences have been reported among IDUs in many
countries. Up to 80% of those acquiring hepatitis C
develop chronic infection and are at risk of developing
cirrhosis and liver cancer. The development of more
effective antiviral therapies means that the uptake of
diagnostic testing for hepatitis C by current and
former IDUs is increasingly important. At the Royal
College of Physicians of Edinburgh’s Consensus
Conference on Hepatitis C, during April 2004, it was
recommended that “a high priority for case finding
should be given to former injecting drug users,
especially those over 40, who are likely to have a stage
of disease which would benefit from treatment”38.
Countries within the UK have developed strategies to
respond to hepatitis C8,9,10 and much of the focus of
these is on current and former IDUs. 
Hepatitis C: England, Wales & Northern Ireland 
20. Up to the end of 2006, laboratories in England had
reported a total of 62,424 diagnoses of hepatitis C
infections to the Centre for Infections (CfI) since
reporting began in 1992. The majority of these
infections will most probably have been acquired
through injecting drug use as over 90% of those
diagnoses with risk factor information gave this as the
route of infection (Table 1). The number of laboratory
reports each year has been increasing since the
introduction of diagnostic tests in the early 1990s,
from under 1,000 per annum prior to 1994 to 8,346 in
2006. Most of this rise probably reflects the increasing
number of those at risk being tested, rather than an
increase in transmission.
21. Laboratories in Wales have reported a total of 4,198
diagnoses of hepatitis C infection; including 428
diagnoses in 2006. Over 90% of infections in
individuals with a known risk factor were associated
with injecting drug use. In Northern Ireland laboratories
have reported a total of 1,049 diagnoses of hepatitis C
infection. In 2006 there were 140 new diagnoses
reported in Northern Ireland, the highest yearly total
reported, and of those reports with exposure data
100% were associated with injecting drug use.
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Figure 2:
Trends in past hepatitis B and C infection among current injecting
drug users* in England & Wales: 1998 to 2006
* Those who started injecting drugs during the four weeks prior to participating in the survey.
Data Source: Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact with drug agencies.
22. The prevalence of hepatitis C infection among IDUs
remains high overall. Of the (current and former) IDUs
participating in the UAPMP agency survey in 2006, two
fifths (41%, 1,316 of 3,240) had antibodies to hepatitis
C **, which is similar to that seen in recent years (2005
42%, 1,325 of 3,175) (Table 1). The overall hepatitis C
prevalence in England was 43% (1,233 of 2,893),
however, there were very marked regional variations
(Figure 1) from 22% (122 of 566) in the North East to
57% (690 of 1,221) in London and 60% (628 of 1,042)
in the North West (data from 2005 and 2006
combined). The prevalence in Wales and Northern
Ireland (Figure 1) were lower than most of the English
regions: combining data from 2005 and 2006, hepatitis
C prevalence in Wales was 18% (66 of 371), and in
Northern Ireland it was 29% (90 of 312). 
23. Those IDUs participating in the UAPMP survey who had
ever been homeless were more like to have antibodies
to hepatitis C (45%, 995 of 2,200) than those who had
not (28%, 220 of 779). 
24. Amongst current IDUs participating in the UAPMP survey
the prevalence of hepatitis C has increased since the
beginning of the decade, from 33% in 2000 (791 of
2,364) to 42% (838 of 1,981) in 2006 (Figure 2). In
England the prevalence among current IDUs in 2006
was 44% (809 of 1,832), whilst combining data for
2005 and 2006 in Wales it was 17% (34 of 199) and in
Northern Ireland, 25% (23 of 92). There were higher
prevalences of hepatitis C infection among several sub-
groups of current IDUs. Those who reported injecting
crack-cocaine in the past four weeks were more likely to
have hepatitis C (59%, 390 of 657) than those who had
not (34%, 448 of 1,324). Higher prevalence was also
associated with the use of some injection sites; those
who had injected into their groins in the past four weeks
were more likely to have hepatitis C (54%, 337 of 623)
than those who had not (37%, 501 of 1,358); and those
who injected into their legs were also more likely to
have hepatitis C (49%, 165 of 338) than those who had
not (41%, 673 of 1,643). 
25. The prevalence of hepatitis C in recent initiates is a
measure of recent transmission, and is one of the
national outcome indicators for the Hepatitis C Action
Plan for England 8. In 2006, among those in this group
who participated in the UAPMP agency survey from
throughout England, Wales and Northern Ireland, the
prevalence was 21% (81 of 388) and similar to that
between 2001 and 2005. However, the prevalence
among this group remains higher than it was in 2000
(11%, 89 of 787) and earlier years (Figure 3)††. An
increase in the level of hepatitis C transmission in the
early part of this decade is supported by the findings of
the cohort study undertaken in London by CRDHB that
estimated the annual incidence to be 42 per 100
person-years50. 
26. The main aim of the NPHS cohort study of IDUs
conducted in South Wales in 2004 was to estimate the
incidence of hepatitis C among IDUs51. It recruited 700
IDUs and followed up 400 of these over approximately
one year. The estimated hepatitis C incidence was 5.9
per 100 person-years, whilst the prevalence of hepatitis
C among all the IDUs recruited at the start of the study
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Figure 3:
Trends in past hepatitis B and C infection among recently initiated injecting drug users* in
England, Wales & Northern Ireland^: 1998 to 2006
* Those who started injecting drugs during the three years prior to participating in the survey.
^ Includes Northern Ireland from 2002.
Data Source: Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact with drug agencies.
** The sensitivity of the oral fluid test used in the UAPMP agency survey is approximately 93%.
††  Data on the prevalence amongst this group for England only will be given in: ‘Hepatitis C in England - The third Health Protection Agency Annual
Report’. The prevalence and trend are very similar to that for England, Wales, and Northern Ireland combined.
was 26% (184 of 700). Those who reported being
homeless during follow-up had a higher incidence of
hepatitis C than those who did not (incidence was 13
per 100 person-years among those reporting up to 6
months homeless in the previous year and 11 per 100
person-years among those reporting 7-12 months
homelessness, whilst among those housed it was 3 per
100 person-years)39. 
27. An increasing proportion of IDUs with hepatitis C are
aware of their infection. Indicating progress with one of
the aims of the ‘Hepatitis C Action Plan for England’ 8
which is to increase the proportion of IDUs with
hepatitis C aware of their infection. Most IDUs who took
part in the UAPMP agency survey in England now report
having accepted the offer of a test, with only 24% of
IDUs (695 of 2,893) reporting never having had a
voluntary confidential test for hepatitis C in 2006,
compared with 51% (1,532 of 2,998) in 2000. Of those
IDUs in England who were infected with hepatitis C,
46% (493 of 1,081) in 2006 were unaware of their
infection, compared to 60% (615 of 1,018) in 2000. Of
participants from Wales 45% (158 of 355) reported
never having a voluntary confidential test for hepatitis C
in 2005/06, with over half (32 of 60) of those with
hepatitis C being unaware of their infection. Less than
one in ten (8.6%, 25 of 292) of the participants from
Northern Ireland in 2005/06 reported not having been
tested for hepatitis C, and just over one quarter (23 of
80) of the participating IDUs with hepatitis C in the
province were unaware of their hepatitis C infection.
Hepatitis C: Scotland
28. During 2005, it was estimated that approximately
50,000 people were infected with hepatitis C in
Scotland (representing 1% of the population)40. Of these
50,000, it was estimated that 37,500 (75%) were
chronically infected (including 33,800 individuals who
had ever injected drugs) and that between 35% and
40% of these had their infection diagnosed40.
29. Of the 33,800 ever IDUs living with chronic hepatitis C
in Scotland during 2005, it was estimated that 22,900,
9,050 and 1,850 had mild, moderate and severe
(cirrhosis) hepatitis C disease, respectively41. Assuming
the continuation of current rates of hepatitis C
transmission and uptake of antiviral therapy, it is
predicted that in the year 2020, 19,000, 18,000 and
3,000 ever IDUs will have mild, moderate and severe
hepatitis C disease, respectively41. 
30. To the end of 2006, a total of 22,073 persons had been
diagnosed hepatitis C positive in Scotland. In 2006,
1,520 new diagnoses were reported; this compares with
an annual average of 1,682 reports during the period
2001 to 2005 (Table 1). Among the 14,755 reports for
which risk information was available, 13,144 (89%) were
known to have ever injected drugs.
31. In Scotland, residual sera from specimens provided by
IDUs, originally tested for HIV, are anonymously tested
for hepatitis C so as to monitor trends in hepatitis C
prevalence among this group42. Table 1 shows that the
prevalence of hepatitis C among IDUs in Glasgow
reduced substantially between 1990 (all IDUs: 89%; IDUs
aged under 25 years: 91%) and 1999/2000 (62%; and
41% respectively), suggesting that there had been a
decrease in hepatitis C incidence during the 1990s.
Since then, the prevalence of hepatitis C among IDUs in
Glasgow has remained broadly unchanged (rising only
slightly in 2002/03, all IDUs: 64%; IDUs aged under 25
years: 43%).
32. A review of epidemiological studies showed that the
incidence of hepatitis C among IDUs in many parts of
Scotland remains high (in the range 12 to 29 per 100
person-years)43.
33. During 2005, a survey of 435 current IDUs recruited at
needles exchanges in Glasgow estimated the sero-
prevalence of hepatitis C was 68%. This compares to a
prevalence of 77% among 531 current IDUs recruited
during a community-wide survey in Glasgow in 200444.
Among 34 IDUs surveyed in 2005 who had commenced
injecting in the previous two years, the prevalence of
hepatitis C was 30%; this prevalence was lower than
that detected among equivalent IDUs surveyed in
2001/2002 (43% of 120) and 2004 (50% of 52). 
34. A recent study modelled the transmission of hepatitis C
through the sharing of used needles/syringes among
IDUs in Glasgow. This combined available information
on: the incidence and cessation of injecting drug use;
the frequencies with which IDUs injected and shared
needles/syringes; and the susceptibility, transmissibility
and carriage of hepatitis C infection. Scenario analyses
indicated that as many as 4,500 hepatitis C infections
had potentially been prevented in Glasgow during 
1988-2000 as a result of harm-reduction measures45.
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Hepatitis B
35. In the UK, hepatitis B infection is usually acquired in
adulthood, with sexual activity or injecting drug use
being the most commonly reported routes of infection.
Infection with the hepatitis B virus typically causes an
acute infection, with a small number of those infected
going on to develop chronic disease. Infection with
hepatitis B is however preventable using a safe and
effective vaccine.
36. In England and Wales, acute hepatitis B cases are
reported to the CfI. There was a substantial
deterioration in the quality of hepatitis B reporting in
2004 and data for 2004 to 2006 are unavailable‡‡.
However, in 2003 injecting drug use was the main risk
associated with hepatitis B infection, accounting for
34% of individuals with a known risk factor in England,
and 27% in Wales. 
37. In Scotland and Northern Ireland, reported hepatitis B
diagnoses encompass both acute and chronic
infections. In Scotland, there were 375 reports in 2006;
this compares to an average annual total of 354 for the
period 2000 to 2005. The proportion of case reports
indicating injecting drug use as the main risk declined
from 30% in 1999 – the year in which an outbreak
occurred among the IDU population in Aberdeen – to
3% in 2006 (Table 1). In Northern Ireland the total
number of reports (acute and chronic) of hepatitis B
infection prior to 2002 had fluctuated at around 30
reports each year. There were 67 reports in 2002, 61 in
2003, 60 in 2004, 72 in 2005 and in 2006 there were
78 reports. Some of these infections will have been
related to injecting drug use. 
38. Overall about one in five IDUs have had hepatitis B
infection. In 2006, 21% (677 of 3,240) of the current
and former IDUs who took part in the UAPMP survey in
England, Wales & Northern Ireland had antibodies to
hepatitis B core antigen (anti-HBc, a marker of previous
or current hepatitis B infection§§; this was similar to the
level seen since 1995 (Table 1). The prevalence varied
by country (combining 2005 and 2006 data), in Wales
the prevalence was 11% (42 of 371) and Northern
Ireland 8.0% (25 of 312). Those IDUs who reported
having ever been homeless were more likely to have
anti-HBc (23%, 495 of 2,200) than those who had not
(17%, 130 of 779). 
39. The transmission of hepatitis B continues, and may have
increased since the middle of the 1990s, even though
there is an effective vaccine. The prevalence of anti-HBc
among recent initiates is an indicator of recent
transmission. The UAPMP survey found that prevalence
among this group increased from 3.4% (20 of 583) in
1997 to 9.1% (35 of 386) in 2003, it was 6.7% (23 of
345) in 2004, 7.1% (28 of 397) in 2005 and 10% (40 of
388) in 2006 (Figure 3).
40. The recent cohort study that followed up current 400
IDUs recruited from South Wales in 2004 estimated the
annual incidence of anti-HBc to be 2.1%51. The
prevalence of anti-HBc among all the IDUs recruited at
the start of this study was 9.3% (65/700). 
Hepatitis A 
41. Up to the end of the 1990s, hepatitis A infection in the
UK occurred most frequently in men who have sex with
men and people who visit endemic countries. There is
an effective vaccine that is offered to those at risk14.
There appears to have been a change in the
epidemiology of hepatitis A in the early part of the
current decade with significant numbers of infections
occurring in IDUs who may have acquired hepatitis A
infection through person-to-person contact either
through poor hygiene, via blood through sharing
contaminated injected equipment, through sexual
activities that increase the risk of oro-faecal
contamination, or from drugs contaminated with faeces
during smuggling. 
42. In 2006, the total number of laboratory reports of
hepatitis A infection in England and Wales was 396 (all
routes of infection). This continues the recent
downward trend in the overall number of hepatitis A
cases reported annually since 2002. There were 460
laboratory reports of hepatitis A in 2005, 671 in 2004,
1,028 in 2003 and 1,357 in 2002. This downward trend
continues to be most notable in men aged between 15
to 44 years. Over the years, there has been an
increasing proportion of hepatitis A reports containing
no information on risk factors. This is reflected in the
fact that in 2005 and 2006, only 0.9% and 0.8% of
reports respectively had information on a recent history
of travelling abroad being associated with hepatitis A
acquisition. In the early part of the decade there had
been a number of outbreaks of hepatitis A that were
associated with injecting drug use and homelessness.
Data since 2002 suggest that the outbreaks of hepatitis
A in IDUs46 have been waning.
43. An outbreak of hepatitis A infection among IDUs in
Scotland occurred in Aberdeen during 2000 and 2001,
and involved 74 IDUs. A case-control study revealed that
poor hygiene, related to individuals preparing and
injecting drugs together, had provided an opportunity
for transmission47. During June to December 2003,
there was an increase in the number of notifications of
hepatitis A in Ayrshire, Scotland; 13 cases among IDUs
were reported48. 
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‡‡ Publication of hepatitis B surveillance data has stopped until the current problems with the routine laboratory surveillance
system, some of which are currently being addressed, have been resolved.  Whilst the quality of the data has been
maintained in parts of the system publishing partial figures could give the false impression that cases of acute hepatitis B in
England and Wales have fallen. The HPA has recently developed surveillance standards for hepatitis B surveillance19.
§§ The sensitivity of the oral fluid test used in the UAPMP agency survey is approximately 75%.
HIV
44. Transmission of HIV through injecting drug use was
recognised early in the HIV epidemic at the beginning
of the 1980s. Explosive outbreaks of HIV infection
among IDUs have occurred worldwide, with ongoing
transmission in Eastern Europe. Other than an outbreak
in Edinburgh in the early 1980s, HIV infection among
IDUs has remained relatively uncommon in the UK,
probably as a result of prompt community and public
health responses.
45. By the end of 2006 there had been a cumulative total
of 4,662 HIV diagnoses reported*** in the UK where
infection was thought to have been acquired through
injecting drug use. These accounted for 5.4% of all HIV
diagnoses to the end of 2006 (86,577) in the UK, 4.2%
(3,325 of 80,001) of those in England, 26% (1,278 of
4,824) in Scotland†††, 3.8% (49 of 1,276) in Wales, and
2.1% (10 of 476) in Northern Ireland.
46. The annual number of HIV diagnoses among IDUs in
recent years has been low and relatively stable (table 1),
at an annual average of 140 reports during the period
1998 to 2006. So far, 156 HIV diagnoses, where infection
was thought to have been acquired through injecting
drug use, have been reported in the UK for 2006 (72 in
London, 16 in Scotland, and 68 elsewhere). Of the 156
new diagnoses in 2006, probable country of infection
was reported for 67% (104). Where reported, 52% (54)
of infections were probably acquired within the UK and
48% (50) outside of the UK, mostly in Southern Europe.
In comparison, in 2004 49% (45 of 91) of infections
were probably acquired in the UK, whilst in 2005 the
figure was 56% (67 of 120). In 2006, country of birth
was reported for 63% (98) of the diagnoses, 45% (44)
were born within the UK and 55% (54) outside of the
UK, mostly in Southern Europe. In 2005 the proportion
born within the UK was 44% (44 of 100).
47. In 2006, 1,038 HIV-infected IDUs were seen for HIV-
related treatment or care in England, Wales & Northern
Ireland, a 19% increase since 2000 when 870 IDUs were
seen for care. IDUs accounted for 4.1% (870 of 21,429)
and 2.1% (1,038 of 49,637) of all HIV-infected
individuals seen for care in 2000 and 2006 respectively.
In 2006, 71% (733 of 1,038) IDUs were male and 88%
(907 of 1,028) were white. One quarter of IDUs seen for
HIV-related care in 2006 had at some time been
diagnosed with an AIDS-defining illness (260 of 1,021).
Whilst 30% (298 of 1,007) of IDUs were not receiving
antiretroviral therapy in 2006, 51% (517) were on a
combination of three drugs and 16% (162) were
receiving four or more drugs (only 30 individuals were
receiving mono or dual drug combinations). Of the IDUs
seen for HIV-related care in 2006 around one fifth (17%,
155 of 915) had latest CD4 counts of 200 cells per mm3
or less‡‡‡. The proportion of IDUs first seen for care in
2006 who had latest CD4 counts of 200 cells per mm3
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*** Based on reports received at the Centre for Infections by the end of June 2007.
††† The high overall proportion of IDUs among the diagnosed HIV infections in Scotland reflects individuals who were infected and diagnosed
early in the epidemic. Since 2002 IDUs have account for around only one in twenty of new HIV diagnoses in Scotland.
‡‡‡ Individuals with CD4 cell counts of 200 cells per mm3 or less have an increased risk of morbidity and mortality relative to individuals with
higher counts. Individuals diagnosed with low CD4 counts have a poorer response to therapy and will have missed opportunities to prevent
onward transmission through clinical and behavioural preventive measures.
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Figure 4:
Prevalence of HIV infection among current and former injecting drug users: 1990 to 2006
^ Includes Northern Ireland from 2002.
Those who started injecting drugs during the three years prior to participating in the survey.
* Data from Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact with drug agencies.
or less was 25% (27 of 106) compared to 27% (20 of
74) in 2000. In Scotland, 387 HIV-infected IDUs were
seen for HIV-related treatment or care in 2006, an 11%
decrease since 2000 when 436 IDUs were seen for care.
IDUs accounted for 33% (436 of 1,310) and 16% (387
of 2,410) of all HIV-infected individuals seen for care in
2000 and 2006 respectively. In 2006, 67% (258 of 436)
IDUs were male and 96% (372 of 387) were white, 16%
of IDUs seen for HIV-related care in 2006 had at some
time been diagnosed with an AIDS-defining illness (63
of 387). Whilst 21% (80 of 387) of IDUs were not
receiving antiretroviral therapy in 2006, 61% (236) were
on a combination of three drugs and 15% (58) were
receiving four or more drugs (only 9 individuals were
receiving mono or dual drug combinations). Of the IDUs
seen for HIV-related care in 2006 around one third
(34%, 132 of 387) had latest CD4 counts of 200 cells
per mm3 or less. The proportion of IDUs first seen for
care in 2006 who had latest CD4 counts of 200 cells
per mm3 or less was 25% (6 of 24) compared to 40%
(8 of 20) in 2000.
48. The overall prevalence of HIV seen among IDUs in 2006
was similar to that seen in recent years, and remains
higher than that seen in the late 1990s. The UAPMP
survey of current and former IDUs in England, Wales &
Northern Ireland indicates an overall HIV prevalence of
1.3% (42 of 3,240) in 2006 (Figure 4). In London, the
prevalence was 4.0% (24 of 593), whilst elsewhere in
England it was 0.65% (15 of 2,300). Combining data for
2005 and 2006 the prevalence of HIV infection among
IDUs in the UAPMP agency survey in Northern Ireland
was 1.9% (6 of 312) and in Wales was 1.1% (4 of 371).
Those IDUs who reported that they had ever been
homeless had a similar prevalence of HIV (1.3%, 28 of
2,200) to those who had not (1.2%, 9 of 779). 
49. The raised HIV prevalence seen among current IDUs in
England and Wales in recent years has continued49. 
The overall prevalence amongst current IDUs in the
UAPMP survey in England and Wales in 2006 was 1.3%
(25 of 1,938). Whilst the HIV prevalence amongst
current IDUs in London has changed little in recent years
(5.0%, 14 of 278 in 2006), elsewhere in England and
Wales it has been elevated since 2004. The prevalence
among current IDUs in England and Wales outside
London in 2006 was 0.66% (11 of 1,660), which is lower
than that seen in 2005 (1.6%, 24 of 1,510) but the
same as that found in 2004 (0.66%, 8 of 1,213). The
HIV prevalence outside London in 2003 was 0.25% 
(3 of 1,206) having changed little since the mid-1990’s.
50. The prevalence of HIV among recent initiates, a
measure of recent transmission, indicated raised levels
of HIV transmission among IDUs in recent years 
(Figure 4). The prevalence among the recent initiates
participating in the UAPMP survey has remained higher
than it was prior to 2003, with the prevalence being
0.77% (3 of 388) in 2006 (in 2002 it was 0.25%, 1 of
400). Corroboration for this comes from the
community recruited cohort study of recently initiated
IDUs in London undertaken by the CRDHB in 2001/03.
This estimated that HIV incidence was 3.4% per annum
overall and provided evidence that the incidence of HIV
was higher among those who reported injecting crack-
cocaine (around 6%). However, in the recent cohort
study of IDUs in South Wales undertaken by NPHS
found that all of the 400 IDUs who were followed up
after approximately one year were negative for
antibodies to HIV51.
51. In 2006, 30% of IDUs (979 of 3,240) who took part in
the UAPMP agency survey reported never having had a
voluntary confidential test for HIV. Of those who had
antibodies to HIV, 64% (25 of 39) were aware of their
infection in 2006, which was higher than in 2005 
(47%, 22 of 47). 
52. In Scotland, the prevalence of HIV among IDUs is
monitored through the surveillance of people
undergoing voluntary confidential HIV testing. This
found a HIV prevalence of 0.79% (17 of 2,142) among
IDUs undergoing testing in Scotland during 2006; this
compares with prevalences of 1.4% to 3.2% in the early
to mid-1990s and 0.5% to 0.9% during the period 1998
to 2005 (Table 1).
HTLV-II (Human T-Cell Lymphotropic Virus, type II)
53. HTLV-II is endemic among native Amerindian tribes52,
and in Europe it has been documented among IDUs53.
HTLV-II infection has been associated with
neurological disorders,54 an increased risk of bacterial
infections, and in those co-infected with HIV an
increased risk of neuropathy55.
54. Between 2002 and 2006 454 individuals were newly
diagnosed with HTLV and reported to CfI, of whom 22
were known to be HTLV-II infected and 10 were HTLV-I&II
co-infected56. Of the 22 individuals diagnosed with HTLV-II
infection the probable route of infection was reported for
8 individuals: 2 were infected through injecting drug use,
2 were infected through heterosexual intercourse with an
IDU partner, 2 were infected through heterosexual
intercourse with no information on the partner, 1 was
infected through transfused blood, and 1 was infected by
mother to child transmission and heterosexual
intercourse. Where reported (12), 10 were born in the UK,
1 in Europe and 1 in Africa. Eleven individuals were tested
as blood donors. As there is no routine testing for the
infection among IDUs, HTLV-II infection among this group
is likely to be under-diagnosed. 
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* Provisional, reports are subject to reporting delay.
# Data on exposure is often incomplete or missing.
^ Includes Northern Ireland from 2002.
~ Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact with drug services.
Indicator
Hepatitis C infection
Reported laboratory diagnoses of 
hepatitis C infection
Proportion hepatitis C antibody positive~‡ 
Prevalence among those having voluntary
confidential HIV tests 
Hepatitis B infection
Reported laboratory diagnoses of hepatitis B
infection
Proportion hepatitis B antibody positive~‡ 
HIV infection
Reports of new diagnoses of HIV infection
through injecting drug use
Prevalence among those having voluntary
confidential HIV tests 
Proportion HIV antibody positive~
Behaviour
Passing on or receiving used needles or syringes
in the last month – self reports~
Sharing of needles and syringes in past month –
agency reports¶
Sharing of any injecting equipment in past
month – self reports~
Markers of health care utilization
Ever used a needle exchange~
Ever had a voluntary confidential test for 
hepatitis C ~
Hepatitis B vaccine coverage – 
self reported~
Proportion of those unaware that they have
hepatitis C infection – self reported~
Proportion of those unaware that they have 
HIV infection – self reported~
Area
England
Wales
Scotland
Northern Ireland
England, Wales &
Northern Ireland^
Glasgow
England
Wales
Scotland**
Northern Ireland***
England, Wales &
Northern Ireland^
London
Scotland
Rest of UK
UK
Scotland
England, Wales & 
Northern Ireland^
England, Wales &
Northern Ireland^
Scotland
England, Wales &
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
Sub-Category
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use#
Current & former injectors
First injected during the last 3 years
Injectors: all ages
Injectors: age under 25 years
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use#
Total number of reports: all exposures 
Current & former injectors
First injected during the last 3 years
Total number of reports: injecting drug use
Total number of reports: injecting drug use
Total number of reports: injecting drug use
Total number of reports: men who have sex with
men & injecting drug use 
All injectors tested
Current and former injectors
First injected during the last 3 years
Current injectors 
Current injectors aged ≤24 
Current injectors who first injected during the 
last 3 years
Current injectors
Current injectors
Current injectors who first injected during the 
last 3 years
Current & former injectors
First injected during the last 3 years
Current & former injectors
Current & former injectors anti-HCV positive
Current & former injectors anti-HIV positive 
n
%
n
%
n
%
n
%
%
%
%
%
n
%
n
%
n
%
n
%
%
n
n
n
n
%
%
%
%
%
%
%
%
%
%
%
%
%
%
Table 1
Summary of indicators of viral hepatitis and HIV transmission among Injecting Drug Users in the United Kingdom
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‡ Denotes past or current infection with hepatitis B/C.
¶ Scottish drug misuse database: data are for financial years, for example, 2002 data relates to 2002/03 financial year.  The data collection process for the Scottish Drug
Misuse Database (SDMD) was revised in April 2006 and is not directly comparable.
** Scottish data can not distinguish between acute and chronic hepatitis B infection.
1990
–
–
–
–
36
50
1
0
–
–
89
91
599
26
19
13
249
22
37
33
21
112
38
61
240
2.8
1.3
0.8
–
–
–
–
–
–
–
–
–
–
–
1991
–
–
–
–
276
31
13
9
–
–
–
–
555
21
17
11
200
25
28
31
7
121
51
72
289
3.2
1.8
0.0
24
35
26
–
–
–
–
–
–
–
–
1992
228
53
13
13
375
57
48
3
–
–
–
–
512
20
19
30
120
18
34
35
16
108
27
54
231
1.9
1.6
0.0
20
27
22
–
–
–
–
–
–
–
–
1993
410
66
25
100
528
84
7
50
–
–
–
–
605
25
24
13
186
9
22
34
13
91
53
60
238
2.9
1.3
0.4
18
25
23
–
–
–
–
–
–
–
–
1994
796
76
43
100
841
88
43
27
–
–
–
–
603
26
30
32
166
10
33
29
10
77
30
60
212
1.5
1.1
0.1
17
25
21
–
–
–
–
–
–
–
–
1995
1,463
80
183
88
1,142
86
63
43
–
–
77
59
584
39
28
55
152
9
30
22
5
102
22
62
221
1.5
1.4
0.2
17
26
22
–
–
–
–
–
–
–
13
1996
2,116
85
411
84
1,238
91
55
53
–
–
80
61
525
41
45
64
184
10
31
22
7
82
34
61
227
1.5
0.6
0.3
18
24
21
28
58
–
–
–
–
–
29
1997
2,652
92
386
97
1,529
91
54
64
–
–
68
43
621
48
31
53
215
11
22
18
3
77
31
63
194
1.4
1.0
0.3
17
25
22
28
55
–
–
–
–
–
38
1998
4,101
90
378
93
1,999
94
65
68
41
12
–
–
806
45
37
71
295
20
18
22
5
58
19
59
165
0.8
0.9
0.4
32
38
31
34
63
–
–
14
25
–
32
1999
5,296
91
429
96
1,954
94
46
78
35
11
712
51
38
54
386
30
24
20
5
54
17
46
139
0.7
0.8
0.1
33
40
31
34
63
–
–
17
29
–
16
2000
4,892
92
341
97
1,890
94
54
82
35
11
704
46
24
35
360
25
42
21
7
51
16
47
148
0.7
0.8
0.0
31
31
24
34
60
84
49
26
35
60
18
2001
4,665
96
292
96
1,682
94
65
75
36
18
–
–
554
37
44
39
357
19
37
21
8
52
18
65
153
0.7
1.0
0.4
33
36
28
35
59
86
54
28
37
59
40
2002
5,547
97
351
99
1,791
92
75
89
39
15
829
37
55
69
354
11
67
22
7
67
11
48
153
0.5
1.0
0.3
34
43
33
33
60
83
58
36
43
58
21
2003
6,187
95
322
100
1,629
92
84
86
42
20
676
38
25
27
342
6
61
22
9
77
13
77
188
0.6
1.2
0.8
29
37
28
34
55
86
63
42
50
53
31
2004
7,993
95
247
100
1,626
92
102
100
41
20
–
–
–
–
–
–
341
6
60
21
7
64
12
62
153
0.5
1.4
0.6
28
36
27
31
55
85
67
51
56
49
49
2005
7,578
97
349
100
1,600
90
134
93
42
16
–
–
–
–
–
–
372
6
72
19
7
59
23
87
186
0.9
1.6
1.3
28
38
28
27
53
84
71
46
59
48
53
2006
8,346*
96
428*
100
1,520
86
140
100
41
21
–
–
–
–
–
–
375
3
78
21
10
72*
16*
68*
167*
0.8
1.3
0.8
23
29
21
–
48
85
75
61
65
45
36
62
41
64
42
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55. IDUs are vulnerable to a range of bacterial infections, such
as wound botulism, ‘gas gangrene’, and bacteraemia, as a
result of non-sterile injecting or injecting contaminated
drugs. In recent years these acute infections have caused
growing public health problems.
Staphylococcus aureus Infections
56. Staphylococcus aureus is a common pathogen among
IDUs, causing infections that vary in severity from
minor skin and soft tissue infections to life-threatening
invasive disease such as bacteraemia and endocarditis.
Typically, isolates from these individuals are meticillin
sensitive S. aureus (MSSA), but little is known about the
extent or epidemiology of MSSA among the IDUs in
the UK. More recently, meticillin resistant S. aureus
(MRSA) has been reported in IDUs in Switzerland and
the United States of America. 
57. A number of laboratories in England and Wales have
reported encountering MRSA as a cause of injecting
drug use related sepsis in the community57,58. The Health
Protection Agency’s (HPA) Staphylococcus Reference
Laboratory (SRL) has received sporadic and small clusters
of isolates for testing. Between April 2003 and March
2007 a total of 60 cases of injecting drug use related
sepsis due to MRSA have been identified from
geographically distinct areas throughout England and
Wales. There were 46 males and 14 females; 30
presented with injection site abscesses or skin infection,
21 with bacteraemia, 4 with endocarditis and 1 with
pneumonia (clinical data were not available for 4). Cases
are continuing to be reported.
58. Detailed analysis of the MRSA isolates has revealed that
they represent a community-associated MRSA (CA-
MRSA) clone that displays a number of characteristic
markers§§§. This clone is distinct from the healthcare-
associated MRSA in the UK (EMRSA-15 and EMRSA-16). In
accordance with international nomenclature, this clone
is known as ST1-MRSA-IV and is one of the most
common CA-MRSA strains currently seen in England and
Wales59 and has been reported previously in Australia60.
It is important to note that this strain does not produce
the Panton-Valentine Leukocidin (PVL) toxin that has
been associated with serious, life-threatening disease.
Nevertheless, as with PVL-positive CA-MRSA strains, this
clone can cause skin and soft tissue infection.
59. The mainly sporadic occurrence of the MRSA strains,
with their geographical and temporal distribution, does
not suggest a drug contamination problem. Continued
surveillance will further our understanding of the
pathogenicity and epidemiology of this unusual clone. 
Group A Streptococcal Infections
60. Group A streptococci (GAS) can cause skin sepsis and
tissue necrosis, potentially leading to bacteraemia
through the infection of injecting sites.
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Bacterial infections
§§§ The MRSA exhibit a distinctive antibiogram (ciprofloxacin susceptible, but fusidic acid and erythromycin resistant), they are lysed by a
broad range of bacteriophages, encode enterotoxins A and H, and belong to clonal complex 1 (CC1).
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Figure 5:
Invasive isolates of group A streptococci from injecting drug user (IDU) and 
non-IDU patients: United Kingdom 1995 to 2006  
* Provisional data.
Data source: Group A streptococci sterile site isolate referrals to the HPA Streptococcus & Diphtheria Reference Unit.
61. Although routine laboratory reports of invasive GAS
infections to CfI rarely contain information on risk factors,
isolate referrals to the HPA’s Respiratory and Systemic
Infection Laboratory (RSIL) do contain such information.
Monitoring of these identified a rise in referrals from
IDUs, from less than 10 per annum in the early to mid-
1990s to 81 in the first nine months of 2002 61. A total of
286 invasive GAS reports in IDUs were received in 2003,
after which time the number of referrals from IDUs fell
markedly to 122 in 2004, levelling off to just under 50 in
2005 and 2006 (Figure 5). 
62. Most cases presented with skin sepsis, bacteraemia and
evidence of tissue damage at the injection site, which
ranged from extensive oedema to necrosis. The majority
were sporadic cases but several clusters were also
identified. Serotyping data have revealed a diverse
range of types****. The geographical and temporal
dissemination along with the serological typing data do
not suggest a drug contamination problem.
63. Enhanced surveillance data gathered during the strep-
EURO programme identified injecting drug use as
being one of the most important risk factors for
severe group A streptococcal infections in the UK,
with just over one fifth of reports being in IDUs. This
proportion was markedly higher than for any other
participating country62. Further epidemiological
investigation will be undertaken to identify any
clustering among these cases.
Clostridial infections 
64. Clostridia are a group of spore-forming bacteria that are
widely found in the environment. The spores produced
by these bacteria may end up in drugs, such as heroin,
through environmental contamination. They may cause
wound infections among IDUs, particularly if they enter
an intramuscular or subcutaneous injection site††††, and
can then produce toxins causing illness such tetanus or
‘gas gangrene’ with potentially severe or fatal outcomes.
Wound botulism 
65. Botulism is an illness caused by toxins produced by the
bacterium Clostridium botulinum. Wound botulism
occurs when wounds, such as injecting sites, are
infected with C. botulinum. Clinical symptoms can
progress rapidly from blurred vision, slurred speech and
muscle weakness to paralysis and respiratory failure. This
can result in hospitalisation and lengthy recovery
periods and in some cases can be fatal. Botulinum
antitoxin is effective at reducing symptoms if given early
in the course of the infection. Wound botulism amongst
IDUs remains rare in the UK. 
66. Prior to 2000 no cases of wound botulism had been
reported among IDUs in the UK63. By the end of 2006 a
total of 134 suspected cases had been reported.
Overall, 113 (84%) of the cases occurred in England, 17
in Scotland, three in Wales, and one in Northern Ireland.
For cases where information was available the ratio of
males to females was 2.5 to 1, and the age ranged from
17 years to 58 years with an average age of 36 years.
There was a wide spectrum of illness severity and speed
of onset, from 1-3 days to 18 days. At least 7 individuals
died. Where information was available, the majority
reported injecting heroin and the average length of
injecting career was 10 years. Of cases during 2004 to
2006 (where information was available) 98% (53 of 54)
were admitted to hospital and 80% (43 of 54) were
admitted to intensive care64. 
67. Cases of wound botulism continue to occur among
IDUs in the UK. In 2006, 22 suspected cases were
reported, fewer than in each of the previous two years,
with 28 cases reported in 2005 and 40 in 2004. Of the
22 cases in 2006, 18 were in England, three in Scotland,
and one in Wales. The cases in England were distributed
throughout the country with reports from seven of the
nine regions65. 
Tetanus
68. A toxin produced by Clostridium tetani causes tetanus. 
It usually presents with local fixed muscle rigidity and
painful spasms confined to the area close to the site of
injury or injection, however symptoms can range from
mild trismus (‘lockjaw’), neck stiffness and/or abdominal
rigidity to generalised tetanus (a serious condition that
can include respiratory difficulties and severe painful
spasms). Tetanus is a vaccine preventable disease, and
the vaccine is routinely offered in childhood and
adolescence as well as to adults for specific indications14.
Potential sources for tetanus infection in IDUs are
contaminated drugs, injecting equipment and skin.
69. Before 2003, tetanus had rarely been reported in IDUs
in the UK, with only two of the 175 cases identified in
England and Wales, through enhanced surveillance
between 1984 and 2000, known to be IDUs66. This was
in contrast to reports from the United States of America
where IDUs accounted for around one in six cases
between 1995 and 200067. The situation changed in
2003 when an outbreak of tetanus developed amongst
IDUs in the UK, with 25 cases reported between 2003
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**** Serotypes M1, R28, M11 and M12 predominated during the years 1995 to 1998 with the emergence of ‘higher types’ during
recent years; M78, M82, M83, M87, M89.  
†††† Tissue damage at intramuscular or subcutaneous injection sites is more likely to lead to an anaerobic environment.
and 200468,69,70. The majority had generalised tetanus
and three cases died. Most cases reported
subcutaneous injection of heroin (‘skin popping’), and
the majority were in women with the male cases being
older. Many cases were un-immunised or partially
immunised and most had tetanus antibody levels below
the protective threshold. The widespread distribution of
the cases suggests that the outbreak may have been
due to heroin being contaminated with tetanus spores
relatively high up in the supply chain. This has led to
vaccination guidance for IDUs being updated to ensure
that their tetanus immunisation status is actively
checked14 and that the use of human tetanus
immunoglobulin is considered for IDUs with injection
site infections. In 2006 there were three cases of
tetanus reported to the HPA in England, one of which
was known to have been an IDU, no cases of tetanus
were reported for the rest of the UK. Whilst in 2005,
four of the six cases of tetanus reported in the UK were
in IDUs, indicating that tetanus continues to affect IDUs,
albeit at lower numbers than in 2003 and 2004.
Other clostridial infections
70. In addition to botulism and tetanus there are other
serious clostridial infections that may be acquired
through injecting contaminated drugs. During 2000
there was an outbreak of serious illness and death
among IDUs, due to Clostridium novyi71,72. Laboratory
work has shown that C. novyi spores can easily survive
the “cooking-up” process prior to heroin injection73.
There have been reports of Clostridium histolyticum
infection among IDUs74, some of whom also had
tetanus. Molecular typing has revealed that isolates from
cases across the UK in 2003 were indistinguishable,
indicating a common source of contamination75. 
Reported Symptoms of Injecting Site Infections
71. Symptoms of a possible injecting site infection would
appear to be common among IDUs, as 35% (655 of
1,882) of IDUs participating in the UAPMP survey in
2006 reported they had experienced either an abscess,
sore or open wound, possible symptoms of an injecting
site infection, during the previous year. The reporting of
such a symptom was associated with having been
homelessness in the last year, with 36% (290 of 800) of
those homeless during the last year reporting a
symptom compared with 30% (289 of 960) of those
not homeless during the last year.
72. These symptoms of possible injecting site infections
were found to be associated with a number of factors
among current IDUs. Overall, 37% (566 of 1,531) of the
current IDUs participating in the UAPMP survey in 2006
reported these symptoms during the last year. Current
IDUs who used certain injection sites reported higher
levels of symptoms: those who had injected in to their
hands were more like to report such a symptom (49%,
183 of 373) than those who had not (33%, 383 of
1,158), and those who injected in to their legs were also
more like to report such a symptom (64%, 182 of 286)
than those who had not (31%, 384 of 1,245). Injecting
crack-cocaine in the past four weeks was also associated
with having had an abscess, sore or open wound, with
43% (238 of 554) those who had injected crack-cocaine
reporting such a symptom compared with 34% (328 of
977) of those who had not.
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73. The transmission of HIV, hepatitis B and C continues
among IDUs in the UK. Overall almost half of IDUs have
been infected hepatitis C, around one in four have been
exposed to hepatitis B, and about one in 75 are now
infected with HIV. In addition, around one in three IDUs
report having had an abscess, open wound or sore (all
symptoms of a possible injecting site infection) during
the last year. The level of needle and syringe (direct)
sharing remains elevated99 with around a quarter of IDUs
reporting direct sharing during the previous month in
2006. The sharing of other injecting related equipment,
particularly mixing containers and filters, is even more
common. 
74. The high level of homelessness among IDUs is a
concern. Around three-quarters of IDUs report having
ever been homeless, and for half of these the last time
was within the past year. Those reporting homelessness
also reported higher levels of risk behaviours, with one
in four of those who had ever been homeless reporting
the direct sharing of needles and syringes compared
with only one in six of those who had not been
homeless. A study in Glasgow has suggested that hostel
living is related to higher levels of risk behaviour36. 
The prevalence of both hepatitis B and C infection, and
the reporting of symptoms of possible injecting site
infections, were higher amongst those who report
having been homeless. Studies have found that
associations with homelessness and hepatitis C infection
remain, even after adjusting for confounders76, whilst
the recent cohort study in Wales has indicated that
homelessness is a key risk factor for hepatitis C
transmission among IDUs39. 
75. The higher levels of risk, and infection, among IDUs who
have experienced homelessness probably reflects the
difficulties faced in maintaining hygienic injection
practice when homeless. Hygienic injection requires a
suitable environment that provides a clean space for
preparing the drug and its injection; somewhere clean
for storing injecting equipment; and facilities for the
safe disposal of used equipment. The role that the
environment in which an injection takes place can have
on injection hygiene and practice has been highlighted
by two Visual Ethnography studies undertaken in
England77 and Scotland78. Homeless IDUs are more likely
to inject in unsuitable environments, often public places
such as in the street, public toilets, or abandoned
buildings; where maintaining hygienic injection practice
will be very difficult79. This may also be a problem for
those who are resident in hostels, if their hostel does
not accommodate their drug use36. Together these
findings suggest that interventions which are aimed at
tackling homelessness could also help in reducing
infections, such as hepatitis C, among IDUs.
76. Concerns about homelessness have resulted in a
number of actions throughout the UK including the
establishment of the Scottish Homelessness Monitoring
Group to support and monitor the implementation of
the recommendations of the Homelessness Task
Force80,81 in 2002, whilst Northern Ireland82, Wales83, and
England84 have national strategies. The English strategy,
for example, aims to halve the number of households
living in temporary accommodation by 2010 through a
range of activities to prevent homelessness84. Whilst
there has been a recent decline in the number of
homeless households in England85, the majority of these
statutory homeless household are however families
with, or expecting children85. Statutory homeless figures
only include those who are accepted by a local authority
as being “owed” a duty under housing legislation. There
will be others with housing problems who will not fall
into this group or who do not even approach local
authorities for help with housing86. Those not counted
will include many single homeless people, who may end
up living in hostels or sleeping rough86. 
77. Individuals living in hostels or sleeping rough often have
complex health and social needs, including high levels
of drug use and mental health problems87,88. In response
to these needs there have been a number of initiatives
including a capital expenditure programme to improve
hostel accommodation89, and the development of
guidance on supporting homeless people with both
mental health and drug problems90. Considering the
associations between homelessness and higher levels of
infection it is important that the ongoing development
of services for the homeless include a full range of
integrated measures to reduce and respond to injection
related infections among homeless IDUs, such as
ensuring easy access to clean injecting equipment,
health checks for injection site infections, and access to
voluntary confidential testing for HIV and hepatitis C.
78. The overall prevalence of hepatitis C among IDUs in the
UK, of almost one in two having been infected, masks
marked regional variations in prevalence. Prevalence
ranges from one in four or less among IDUs in Wales
and the North East of England to more than half of IDUs
in London, Glasgow, and the North West of England.
The existence of lower prevalence areas suggest that
hepatitis C infection is probably not an inevitable
consequence of injecting drug use, despite IDUs often
depicting hepatitis C as ubiquitous and “beyond
prevention”91. The reasons for these geographic
variations in prevalence are currently unclear and
require further examination. They will, in part, reflect
differing levels of incidence as the recent cohort studies
have found a more than six-fold difference in incidence
between London50 and Wales51. Worryingly, there is
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Comments & Conclusions 
evidence to indicate that the transmission of hepatitis C
among IDUs may have increased since the beginning of
the current decade, for example, the prevalence among
recent initiates has increased from around one in ten to
about one in five. Even so, the overall hepatitis C
prevalence among IDUs in the UK is lower than in many
other countries, and data from Glasgow suggest a
decline in prevalence during the 1990s, so in part the
current prevalence might reflect benefits of the
interventions introduced in the late 1980s and early
1990s in response to HIV. Exploration of longer-term
trends in hepatitis C prevalence among IDUs in England
and Wales, through the testing of stored samples from
the early 1990s, will provide further evidence.
79. Associations between crack-cocaine use and higher
levels of hepatitis C infection and injecting risk are a
concern. Particularly as there is evidence to indicate that
the use and injection of crack-cocaine is becoming
more common92, with around one-third of IDUs now
reporting injecting crack-cocaine. However, there is a
need to further investigate the associations between
crack-cocaine use and risk, as the extent to which
factors such as homelessness, the injecting environment
and injecting practices interplay with crack-cocaine
injection remain unclear76,77. There is also evidence that
groin injecting, which is particularly risky, has become
more commonplace and acceptable93, with around one-
third of IDUs now reporting this. 
80. The proportion of IDUs in contact with drug services
self-reporting having ever had a voluntary confidential
test for hepatitis C has increased markedly over recent
years with three-quarters now reporting ever accepting
the offer of a test. However, almost half of IDUs with
hepatitis C infection in contact with drug services in
England and Wales are still unaware of their infection. It
is likely that a greater proportion of those with hepatitis
C who are not in contact with drug services will be
unaware of their infection. 
81. The prevalence of HIV among IDUs in the UK remains
higher than it was at the beginning of the decade,
however it is still low compared with many other
countries. The prevalence remains elevated among
current IDUs in London with around one in 20 infected,
elsewhere in England and Wales the prevalence was
about one in 150 in 2006, up from around one in 400
in 2002. In Scotland, one in 130 IDUs are probably
infected with HIV and this has changed little in recent
years. There is evidence of ongoing HIV transmission
within the UK and that this has probably increased in
recent years. In particular, the HIV prevalence amongst
recent initiates, those injecting for less than three years,
has been elevated since 2002. Whilst the annual
number of reports of newly diagnosed HIV infections
associated with injecting drug use has not changed
greatly over recent years, the proportion thought to
have been acquired abroad has declined. 
82. The continuing occurrence of wound botulism cases is a
concern, and cases have also been reported in several
other European countries in recent years94,95,96,97,98.
Healthcare workers should remain alert to the possibility
of clostridial infections among IDUs, particularly those
who inject subcutaneously or intramuscularly, risk
factors associated with wound botulism. 
83. The reasons for the continuing occurrence of MRSA
and severe GAS infections are unclear and need
further investigation. The increased occurrence of
bacterial infections at injection sites might reflect an
increased vulnerability of IDUs due to changes in risk
behaviour99, which might be associated with the
increased use of crack-cocaine92. The increases in GAS
cases up to 2003 may have been, in part, due to
increased awareness and microbiological investigations
following the outbreak of severe illness due to
Clostridium novyi in 200071,100, however, the trend pre-
dates this. Furthermore, findings from a GAS cluster in
London, where risk factor information and routine
sampling had been undertaken consistently since
1970, argue against increased ascertainment as the
sole explanation101. The subsequent recent decrease in
severe GAS infection reports, particularly in specific
areas in the north of England where previous increases
have been reported102, may be attributable to the
success of targeted healthcare interventions, but this
has yet to be confirmed. 
84. NEX schemes are the key service for reducing infections
and maintaining good injection hygiene as they provide
sterile injection equipment, information and advice. The
results of the national audits of NEX undertaken in
200520,21 indicated a great diversity in provision across
the UK. The findings also supported previous concerns
about the coverage of NEX services and that this might
be insufficient24. The NEX audit indicated that almost
80% of NEX sites were situated in pharmacies103.
Agency-based NEX (that is standalone NEXs or NEXs
based in multi-services drug agencies) typically provide
a wider range of other services, such as face-to-face
advice and on-site vaccination, than pharmacy-based
services. Those commissioning services should monitor
NEX provision to ensure accessible provision of sufficient
needles and syringes to prevent sharing, and that this
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provision is responsive to changing patterns of drug use
and risk. In England a national monitoring system of NEX
throughput of injecting equipment is being developed
by the NTA.  
85. The significant reductions in both the frequency of
injecting and rates of direct sharing reported among
recent initiates in Glasgow104, following revised
guidelines by Scotland's Lord Advocate allowing greater
numbers of needles and syringes to be obtained per
NEX visit, are encouraging. While these changes may
have stemmed from factors other than the increased
availability of needles and syringes, the study
concluded that “it would seem prudent to continue
with the current new policy on needle and syringe
distribution”104 and IDUs should be encouraged to make
use of their entitlement to a greater number of sterile
needles and syringes.
86. Infections, such as hepatitis C, may be reduced by the
provision of sterile injecting equipment other than
needles and syringes, such as mixing containers; whilst
the correct use of sterile swabs before injection could
help reduce bacterial infections at injecting sites.
Results from the NEX audits20,21 and from the 2006
drug services user satisfaction survey in England105
suggest that there is currently great variability in the
range of injecting equipment offered to clients in
addition to needles and syringes, and that provision is
not related to need. Those commissioning services
should monitor NEX provision to ensure appropriate
local provision of sterile water, swabs, mixing
containers, citric acid, and filters. 
87. Around one in five injectors have been infected with
hepatitis B, and new infections are continuing to occur.
Vaccine coverage continues to increase with the
majority of IDUs now having taken up the offer of
vaccination. There is however wide regional variations in
the levels uptake of the hepatitis B vaccination105. 
The overall improvement in uptake of the vaccine
probably reflects improved provision through drug
services and the prison vaccination programmes106. 
In England the majority of prisons offer vaccination, and
with Primary Care Trusts now responsible for delivering
prison health services, vaccine provision through prisons
should improve further. Since the Scottish Prison Service
introduced its hepatitis B vaccination programme to all
inmates in 1999, there have been no outbreaks of acute
hepatitis B infection among IDUs in Scotland35. 
88. Following the recent outbreaks of tetanus68 and
hepatitis A46 consideration should be given to offering
vaccination or boosters against these infections as
appropriate. Introducing hepatitis A vaccination14,107 in
conjunction with existing hepatitis B vaccination
programmes should be examined. A combined hepatitis
A and B vaccine is available and this may be more
popular with clients than offering the single vaccines
together107. Health professionals in contact with IDUs
should also ask clients about their tetanus immunisation
status. IDUs who have not received five doses of tetanus
vaccine, or who are unsure of their vaccination status,
should be offered vaccination boosters as appropriate.
Unvaccinated IDUs should be encouraged to complete a
full course of tetanus vaccinations14. 
89. The recent National NEX audits20,21 indicate that amongst
agency-based specialist NEX services, at most only half
provided on-site hepatitis B vaccination and at most
one-quarter offered hepatitis A vaccination. Provision of
the tetanus vaccine was even less common. These
findings support other indications that NEX services are
less likely to provide hepatitis B vaccine doses to IDUs
than prisons or drug treatment services106. It is of
concern that so few NEX services report providing onsite
vaccination, given that these are likely to be the first
drug service that new IDUs will come into contact with.
In England the NTA performance manages the offer of
vaccination through drug services using the annual drug
treatment plan.
90. Since the late 1990s the focus of policy2,32 around drug
use has broadened from a public health perspective to
the minimisation of wider social harm, including crime
and anti-social behaviour108. This has led to an expansion
of treatment services that aim to help people stop using
drugs. The current drug strategy also identifies the
need for further action to “improve the health of drug
misusers and drive forward action to reduce the risk of
death”2. Considering the current extent of injecting
related infections, services should be commissioned to
provide clear information and practical advice on safer
injecting practices, avoiding injecting site infections,
prevention of blood-borne virus transmission, and the
safe disposal of used equipment; on-site access to
vaccination and voluntary confidential testing services;
basic health checks for injection site infections; and
easy referral to treatment services for those who wish
to modify or reduce their drug use. The recent update
of Models of Care16, which provides a framework for
the provision of treatment to drug users in England,
sets a clear structure for the provision of these
services, and NEX, across the range of agencies
working with drug users. 
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91. The Treatment Outcomes Profile (TOP) which was
launched by the NTA on 1st April 2007, will be the
first standard outcome monitoring tool to be
implemented into any national drug treatment
system. This short validated data collection tool, is
comprised of twenty questions which enable the
drugs workers to regularly monitor key treatment. In
England TOP data is being collected by the National
Drug Treatment Monitoring System from October 1st
2007. The TOP includes detailed questions on drug
and alcohol use, injecting risk behaviour, criminal
activity, social functioning and physical and mental
health, and its regular completion will enable
assessment of the impact of treatment services on
actual client behaviour including injecting risk.
92. In England Substance Misuse Improvement Reviews
were launched as partnership between the NTA and
Heathcare Commission in 2005. These reviews provide
independent assessments of the drug treatment
services in each Drug Action Team (DAT) area to
facilitate improvements in key aspects of services. The
2006/7 Improvement Review included provision of harm
reduction services (those services that aim reduce
harms such as infections among those who continue to
use drugs). Areas were assessed against the following
criteria: harm reduction was being embedded in the
local drug treatment system; service users have prompt
and flexible access to needle exchange services,
vaccination, testing and treatment for blood born
viruses; action is taken to reduce the number of drug-
related deaths; and the staff were competent to deliver
effective harm reduction services. In autumn 2007 the
performance scores will be published, and help will then
be given to the organisations (approximately 10%) that
receive the weakest assessments to develop an action
plan to improve their performance. These scores will
also provide local areas with a baseline against which
they can measure improvements. 
93. The Department of Health, with the NTA, has recently
launched an action plan for reducing drug related harm
in England which includes infections as one of its
focuses. This plan includes actions to provide targeted
health promotion campaigns, including work on
hepatitis B immunisation; to improve delivery of harm
reduction messages such as through the development
of good practice standards for needle and syringe
programmes; and to improve the quality and availability
of surveillance information including data on hepatitis C
prevalence and on drug related deaths update. This will
also include an update of the guidance on hepatitis C
for those working with drug users. These actions build
upon those set out in the Hepatitis C Action Plan for
England8 and complement the service framework set
out in Models of Care16. 
94. The National Institute for Health and Clinical Excellence
(NICE) published technical appraisals and guidelines
relating to the appropriate provision of methadone,
buprenorphine, opioid detoxification13, and psychosocial
interventions12. An update of the national guidance –
Drug Misuse and Dependence Guidelines for Clinical
Management11 – has also been published recently. 
The need for harm reduction interventions is highlighted
in all these publications. Commissioners and providers
of services for drug users will need to ensure that these
are addressed when planning and implementing
services in response to local need. 
95. In 2006, the Scottish Executive Health Department
published its first Hepatitis C Action Plan9. This Plan
covers a two-year period from September 2006 to
August 2008 and will, in part, lay the foundation for
further long-term action beyond September 2008. 
The overall aims of the Scottish Action Plan are: to put
in place mechanisms to ensure better coordination,
planning and accountability of services; to build on
existing activities and interventions to reduce the
number of new cases of hepatitis C in Scotland; to
provide professionals and service users with the
information and support they need; and to gather
robust data to inform the development and expansion
of testing, treatment and care services beyond 2008.
The Action Plan acknowledges that efforts to prevent
hepatitis C in Scotland must focus on preventing
transmission among IDUs, through improving the
accessibility and effectiveness of drug treatment,
rehabilitation, needle exchange and other harm
reduction services. 
96. An Action Plan for the Prevention, Management and
Control of Hepatitis C in Northern Ireland was
launched in January10. This contains a range of actions
to address hepatitis C in Northern Ireland, a number of
which are targeted at IDUs. These include raising
awareness of risk behaviours amongst IDUs; training,
information and guidance on blood borne viruses for
professionals; development of local multi-agency
arrangements for hepatitis C prevention; and further
development of NEX schemes.
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97. There is a need for research and development projects,
to pilot and evaluate innovative intervention options for
improving injection hygiene, such as novel approaches
to providing practical training to IDUs on safer
injecting. Such projects should draw upon the lessons
learnt in other countries such as the pilots of Drug
Consumption Rooms (DCR)109,110,111. A pilot of a DCR
facility within the UK has been recommended by both
an expert group convened by the Joseph Rowntree
Foundation in 2006112 and the Home Affairs Select
Committee in 2002109 but there remain legal issues
relating to their operation within the UK. There is also a
need to examine the appropriate mix and coverage of
a range of existing interventions in the UK that aim to
prevent infections, including specialist drug treatment,
NEX, and targeted outreach.
98. There would appear to be a need for research studies to
explore the factors that impact on injecting risk
behaviour and how these interact with one another.
Factors considered should include homelessness,
injecting in public and semi-public places, and the
increasing acceptability of groin injection, as well as the
growing use of crack-cocaine. In addition, there is a
need to explore the feasibility of interventions designed
to prevent, or reduce, initiation of drug injecting among
non-injecting drug users. 
99. IDUs in the UK are continuing to contract a wide range
of infections, and public health surveillance systems
need to be maintained and developed to provide
continued vigilance. Systems to improve our
understanding of the extent of injecting site infections
need to be investigated and developed. There is
ongoing work to improve surveillance of viral hepatitis
as part of the implementation of national standards for
the surveillance of hepatitis B and C in the HPA19,
through the collation at a national level data on acute
hepatitis B cases from local health protection units.
Provisional data will be available from the start of 2007,
however the quality and completeness of this
information is uncertain, and the interpretation of
trends in incidence will be difficult, given the lack of
baseline data. 
100. The UAPMP agency survey continues to provide
valuable data on blood-borne viruses and associated
risks among IDUs in contact with services. The UAPMP
enhancement pilot provided important additional data,
particularly on behaviours and drug use, and its
continuation needs to be considered by the HPA. The
ongoing development of a companion unlinked
anonymous survey in Scotland should in the future
provide comprehensive UK-wide data. 
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Notifiable diseases
Tetanus. Laboratories are requested to report all confirmed cases to CfI in England, to the NPHS in Wales, to
CDSC in Northern Ireland and to HPS in Scotland. Information and advice for clinicians, microbiologists and
injecting drug users is available at: www.hpa.org.uk/infections/topics_az/tetanus/menu.htm and from HPS for
Scotland at www.hps.scot.nhs.uk/immvax/tetanus.aspx?subjectid=126
Information on reference laboratory services for tetanus are included in the RSIL user manual at:
www.hpa.org.uk/srmd/div_rsil/rsiluser.pdf
Hepatitis A. Laboratories are requested to report all confirmed cases to CfI in England, to the NPHS in Wales, to
CDSC in Northern Ireland and to HPS in Scotland. Information and advice for clinicians and injecting drug users
in England and Wales is available on the HPA website at:
www.hpa.org.uk/infections/topics_az/hepatitis_a/menu.htm
Hepatitis B & C. Laboratories are requested to report all confirmed cases to CfI in England, to the NPHS in
Wales, to CDSC in Northern Ireland and to HPS in Scotland. 
Further information can be found for hepatitis B at www.hpa.org.uk/infections/topics_az/hepatitis_b/menu.htm
and www.hps.scot.nhs.uk/bbvsti/hepatitisb.aspx?subjectid=92
Further information can be found for hepatitis C at www.hpa.org.uk/infections/topics_az/hepatitis_c/menu.htm
and www.hps.scot.nhs.uk/bbvsti/Hepatitisc.aspx?subjectid=93
Support for management of individual cases and their contacts and of outbreaks is available at local level from
the Health Protection Unit and at national level from CfI and the NPHS in Wales, CDSC Northern Ireland and HPS
(Scotland). Policy advice on vaccination (tetanus, hepatitis A & B) is developed for the UK by the UK Joint
Committee on Vaccination and Immunisation. Policy advice for viral hepatitis is developed for the UK by the
Department of Health Advisory Group on Hepatitis.
Other infections
Wound botulism. Information and advice for clinicians and injecting drug users in England and Wales is
available on the HPA website at: www.hpa.org.uk/infections/topics_az/botulism/menu.htm
Laboratory investigation of cases of botulism (detection of neurotoxin and isolation of Clostridium botulinum):
Food Safety Microbiology Laboratory, CfI, HPA, 61 Colindale Ave, London NW9 5EQ. Telephone: 020 8200 4400
Other clostridia infections. Identification of other clostridial, or other anaerobic, isolates from IDU wounds,
blood and cultures: Anaerobe Reference Laboratory, NPHS Microbiology Cardiff, University Hospital of Wales,
Cardiff, CF14 4XW Tel: 02920 742378 or 742171
Group A streptococci. Information and advice for clinicians in England and Wales is available on the HPA
website at: www.hpa.org.uk/infections/topics_az/strepto/non_pyogenic/HPA_Group_A_streptococci_Default.htm
Information on reference laboratory services for GAS are included in the RSIL user manual at:
www.hpa.org.uk/cfi/rsil/default.htm
Staphylococcus aureus infections. Information and advice for clinicians is available on the HPA website at
www.hpa.org.uk/infections/topics_az/staphylo/default.htm . Identification and characterisation of MSSA and
MRSA from IDUs: Staphylococcus Reference Unit, CfI, HPA, 61 Colindale Avenue, London, NW9 5EQ. 
Telephone: 020 8327 7227.
Appendix: Sources of information and advice on
reporting infections and investigating outbreaks
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Reports of HIV infection
Voluntary confidential reports of new HIV diagnoses are
received from laboratories and clinicians in England, Wales,
and Northern Ireland by CfI. Scottish and paediatric data is
collected locally and incorporated with data from England,
Wales and Northern Ireland on a quarterly basis to create a
UK dataset. Surveillance began in 1982 with AIDS case
reporting, and expanded to include laboratory reporting of
HIV diagnoses in 1985. In England, Wales, and Northern
Ireland, clinician HIV reports were introduced in 2000 to
supplement laboratory reporting, and the AIDS information
is now collected on the clinician HIV report.  
HIV infected individuals accessing HIV-related care
A cross-sectional survey is carried out to identify all
individuals with diagnosed HIV infection who attend for HIV
related care at NHS sites in England, Wales and Northern
Ireland within a calendar year. Scottish and paediatric data is
collected locally and incorporated annually to create a UK
dataset. This survey has been repeated annually since 1995.
Laboratory reports of viral hepatitis & bacterial
infection
Clinically significant infections diagnosed in England, Wales
and Northern Ireland are routinely reported to CfI and held
on a central system known as LabBase2. Most laboratories
participate in the system, even if reporting is not mandatory.
LabBase2 is therefore one of the most comprehensive
sources of surveillance data, covering nearly all
microbiologically-confirmed infections. Data on infections
caused by group A streptococci and hepatitis A, B and C
were all extracted from this reporting system. These reports
contain demographic and risk information, although the risk
factor information is not always provided. In Scotland, HPS
collates data on all confirmed hepatitis C antibody tests
from the main hepatitis C testing laboratories in Glasgow,
Edinburgh, Dundee and Aberdeen.  
The Unlinked Anonymous Prevalence Monitoring
Programme’s Survey of Injecting Drug Users
The UAPMP aims to measure the distribution of infection in
sub-groups of the adult population. In the surveys that make
up the UAPMP, samples are irreversibly unlinked from any
identifying information before testing. The UAPMP’s surveys
have ethical approval. 
The UAPMP survey of IDUs monitors HIV, hepatitis B and
hepatitis C in injectors in contact with specialist services,
such as needle exchanges, or on treatment programmes,
such as methadone maintenance. Those who agree to
participate provide a oral fluid sample and complete a
behavioural questionnaire. Detailed methods used for the
survey have been published previously1. The survey of IDUs
has been ongoing since 1990 in England & Wales, and was
extended to Northern Ireland in 2002.
Further information about the UAPMP and comprehensive
tables of data are available at:
www.hpa.org.uk/infections/topics_az/hiv_and_sti/hiv/epide
miology/ua.htm
A pilot of an enhancement to the UAPMP survey of IDUs
started in 2003. This collaboration between CRDHB and the
CfI uses fieldworkers to target recruitment in settings where
the UAPMP agency survey is difficult to deploy, such as
mobile needle exchanges and through community
recruitment. Dried blood spot specimens are collected
rather than oral fluid samples.  
Reference laboratory submissions
The key source of data on MRSA infections in IDUs is through
referral of isolates to the SRU (part of CfI) for reference
microbiology. 
Isolate referrals to the national reference laboratory RSIL
(part of CfI), are one of the primary sources of GAS infection
reports (see strep-EURO below).
Data on clostridial infections are also available from
reference microbiology work. For botulism this is carried out
by FSML, and for tetanus by RSIL. For the other clostridia this
is undertaken by the Anaerobe Reference Laboratory, NPHS
Microbiology Cardiff.
Strep-EURO 
Data from reference laboratory isolates and routine
laboratory reports were combined as part of a two year
enhanced surveillance programme (2003-04). Augmented
surveillance data were sought through questionnaires sent
to microbiologists nationally. Data reconciliation between
the two sources has been maintained since the end of the
project.
Notifications of infectious diseases
Clinicians throughout the UK are required by law to report a
number of defined conditions to their local communicable
disease specialist. Tetanus and hepatitis A, B and C are
among these notifiable diseases.
Enhanced surveillance of tetanus 
Enhanced surveillance of tetanus is carried out by the CfI
Immunisation Department
www.hpa.org.uk/infections/topics_az/tetanus/menu.htm
Surveillance of wound botulism 
Surveillance of wound botulism among IDUs is carried out
by the CfI HIV & STI Department, with FSML. Reports are
followed up with a surveillance questionnaire.
HTLV 
The HIV & STI Department at CfI collates reports of new
HTLV diagnoses in England and Wales from laboratories and
clinicians.
Data sources
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